Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas

被引：0
|
作者：
T. Ebata
M. Yunokawa
S. Bun
A. Shimomura
T. Shimoi
M. Kodaira
K. Yonemori
C. Shimizu
Y. Fujiwara
T. Kato
K. Tamura
机构：
[1] Chiba University,Department of Medical Oncology
[2] National Cancer Center Hospital,Department of Breast and Medical Oncology
[3] National Cancer Center Hospital,Department of Pharmacy
[4] National Cancer Center Hospital,Department of Gynecology
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Ovarian cancer; Carboplatin; Paclitaxel; Dose-dense therapy; Neoadjuvant chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1283 / 1288
页数：5
相关论文
共 50 条
  • [31] Dose-dense Paclitaxel in Advanced Ovarian Cancer
    Kumar, A.
    Hoskins, P. J.
    Tinker, A. V.
    CLINICAL ONCOLOGY, 2015, 27 (01) : 40 - 47
  • [32] Carboplatin and paclitaxel dose dense as neoadjuvant chemotherapy follow by interval cytoreduction in advanced ovarian cancer.
    Alcarraz, Cindy
    Olivera, Mivael
    Muniz, Johana
    Morante, Zaida
    Ruiz, Rossana
    Valdiviezo, Natalia
    Mas Lopez, Luis Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Benefits of neoadjuvant chemotherapy in ovarian, primary peritoneal, or fallopian tube carcinoma.
    Brown, Alaina J.
    Huang, Marilyn
    Sun, Charlotte C.
    Zaid, Tarrik M.
    Balakrishnan, Nyla
    Mhadgut, Hemendra
    Lu, Karen H.
    Westin, Shannon Neville
    Bodurka, Diane C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Carboplatin plus paclitaxel weekly dose-dense chemotherapy for high-grade ovarian cancer: A re-evaluation
    Kessous, Roy
    Matanes, Emad
    Laskov, Ido
    Wainstock, Tamar
    Abitbol, Jeremie
    Yasmeen, Amber
    Salvador, Shannon
    Lau, Susie
    Gotlieb, Walter H.
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2021, 100 (03) : 453 - 458
  • [35] Dose-dense chemotherapy in advanced ovarian cancer
    Bookman, Michael A.
    LANCET, 2009, 374 (9698): : 1303 - 1305
  • [36] DOSE-DENSE PACLITAXEL AND CARBOPLATIN PLUS BEVACIZUMAB IS AN EFFECTIVE AND A TOLERABLE FIRST-LINE REGIMEN FOR ADVANCED OVARIAN CANCER
    Komazaki, H.
    Takahashi, K.
    Tanabe, H.
    Shoburu, Y.
    Izumi, A.
    Kamii, M.
    Tsuda, A.
    Saito, M.
    Yamada, K.
    Takano, H.
    Niimi, S.
    Okamoto, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A169 - A170
  • [37] Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers
    Escobar, PF
    Markman, M
    Rose, P
    Zanotti, K
    Webster, K
    Belinson, J
    GYNECOLOGIC ONCOLOGY, 2004, 92 (01) : 192 - 196
  • [38] Dose-dense paclitaxel for advanced ovarian cancer Reply
    Katsumato, Noriyuki
    LANCET, 2010, 375 (9711): : 281 - 281
  • [39] Dose-dense chemotherapy with weekly paclitaxel and 3-weekly carboplatin for recurrent ovarian cancer
    Chen, Wei-Chun
    Huang, Huei-Jean
    Chang, Ting-Chang
    Chou, Hung-Hsueh
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2020, 59 (01): : 21 - 27
  • [40] A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer
    Fujiwara, Keiichi
    Aotani, Eriko
    Hamano, Tetsutaro
    Nagao, Shoji
    Yoshikawa, Hiroyuki
    Sugiyama, Toru
    Kigawa, Junzo
    Aoki, Daisuke
    Katsumata, Noriyuki
    Takeuchi, Masahiro
    Suzuki, Mitsuaki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (02) : 278 - 282
12345